114 related articles for article (PubMed ID: 2690225)
21. Radiation dose selection in Hodgkin's disease patients with large mediastinal adenopathy treated with combined modality therapy.
Elconin JH; Roberts KB; Rizzieri DA; Vermont C; Clough RW; Kim C; Dodge RK; Prosnitz LR
Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1097-105. PubMed ID: 11072168
[TBL] [Abstract][Full Text] [Related]
22. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial.
Hutchinson RJ; Fryer CJ; Davis PC; Nachman J; Krailo MD; O'Brien RT; Collins RD; Whalen T; Reardon D; Trigg ME; Gilchrist GS
J Clin Oncol; 1998 Mar; 16(3):897-906. PubMed ID: 9508171
[TBL] [Abstract][Full Text] [Related]
23. Prognostic factors of Hodgkin's lymphoma and their impact on response to chemotherapy and survival.
Abdel Hamid TM; El Zawahry HM; Khattab NA; Mowafy TM; Awaad MM; Ali El-Din NH; Mokhtar NM
J Egypt Natl Canc Inst; 2005 Mar; 17(1):9-14. PubMed ID: 16353077
[TBL] [Abstract][Full Text] [Related]
24. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
Eich HT; Diehl V; Görgen H; Pabst T; Markova J; Debus J; Ho A; Dörken B; Rank A; Grosu AL; Wiegel T; Karstens JH; Greil R; Willich N; Schmidberger H; Döhner H; Borchmann P; Müller-Hermelink HK; Müller RP; Engert A
J Clin Oncol; 2010 Sep; 28(27):4199-206. PubMed ID: 20713848
[TBL] [Abstract][Full Text] [Related]
25. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
Engert A; Schiller P; Josting A; Herrmann R; Koch P; Sieber M; Boissevain F; De Wit M; Mezger J; Duhmke E; Willich N; Muller RP; Schmidt BF; Renner H; Muller-Hermelink HK; Pfistner B; Wolf J; Hasenclever D; Loffler M; Diehl V;
J Clin Oncol; 2003 Oct; 21(19):3601-8. PubMed ID: 12913100
[TBL] [Abstract][Full Text] [Related]
26. Prognosis of high dose chemotherapy/autologous bone marrow transplantation candidates not receiving this treatment after failure of primary therapy of Hodgkin's disease.
Fuchs R; Löffler M; Pfreundschuh M; Dölken G; Gerhartz H; Hagen-Aukamp U; Hiller E; Petsch S; Pflüger KH; Rühl U
Leuk Lymphoma; 1994 Jun; 14(1-2):79-89. PubMed ID: 7522721
[TBL] [Abstract][Full Text] [Related]
27. Long-term follow-up of salvage radiotherapy in Hodgkin's lymphoma after chemotherapy failure.
Campbell B; Wirth A; Milner A; Di Iulio J; MacManus M; Ryan G
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1538-45. PubMed ID: 16125872
[TBL] [Abstract][Full Text] [Related]
28. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
29. Analysis of long-term results and prognostic factors among 138 patients with advanced Hodgkin's disease treated with the alternating MOPP/ABVD chemotherapy.
Brusamolino E; Orlandi E; Morra E; Castelli G; Pagnucco G; Livraghi A; Astori C; Santagostino A; Lazzarino M; Bernasconi C
Ann Oncol; 1994; 5 Suppl 2():53-7. PubMed ID: 7515648
[TBL] [Abstract][Full Text] [Related]
30. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V
Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751
[TBL] [Abstract][Full Text] [Related]
31. Hodgkin's disease in elderly patients (> or =60): clinical outcome and treatment strategies.
Kim HK; Silver B; Li S; Neuberg D; Mauch P
Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):556-60. PubMed ID: 12738333
[TBL] [Abstract][Full Text] [Related]
32. The EORTC treatment of early stages of Hodgkin's disease: the role of radiotherapy.
Tubiana M; Henry-Amar M; Hayat M; Burgers M; Qasim M; Somers R; Sizoo W; van der Schueren E
Int J Radiat Oncol Biol Phys; 1984 Feb; 10(2):197-210. PubMed ID: 6368491
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors for subdiaphragmatic involvement in clinical stage I-II supradiaphragmatic Hodgkin's disease: a retrospective analysis of the GHSG.
Rueffer U; Sieber M; Josting A; Breuer K; Grotenhermen FJ; Bredenfeld H; Tesch H; Nisters-Backes H; Engert A; Diehl V
Ann Oncol; 1999 Nov; 10(11):1343-8. PubMed ID: 10631463
[TBL] [Abstract][Full Text] [Related]
34. Results of the 1988-1989 Patterns of Care Study process survey for Hodgkin's disease.
Smitt MC; Stouffer N; Owen JB; Hoppe RT; Hanks GE
Int J Radiat Oncol Biol Phys; 1999 Jan; 43(2):335-9. PubMed ID: 10030258
[TBL] [Abstract][Full Text] [Related]
35. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results.
Viviani S; Bonadonna G; Santoro A; Bonfante V; Zanini M; Devizzi L; Soncini F; Valagussa P
J Clin Oncol; 1996 May; 14(5):1421-30. PubMed ID: 8622055
[TBL] [Abstract][Full Text] [Related]
36. [A retrospective analysis of the treatment results in Hodgkin's disease in a radiotherapy clinic].
Mjaaland I; Ganser D; Freitag EM; Bohndorf W
Strahlenther Onkol; 1994 Sep; 170(9):516-23. PubMed ID: 7524173
[TBL] [Abstract][Full Text] [Related]
37. ABVD and radiation therapy as first-line treatment in advanced Hodgkin's disease.
Zinzani PL; Magagnoli M; Frezza G; Barbieri E; Gherlinzoni F; Galuppi A; Bendandi M; Merla E; Albertini P; Babini L; Tura S
Leuk Lymphoma; 1999 Feb; 32(5-6):553-9. PubMed ID: 10048428
[TBL] [Abstract][Full Text] [Related]
38. Risk-adapted therapy with three or six cycles of doxorubicin/bleomycin/vinblastine/dacarbazine plus involved-field radiation therapy in Hodgkin lymphoma, based on prognosis at diagnosis and early response: results from the GATLA study.
Pavlovsky S; Corrado C; Pavlovsky MA; Prates MV; Zoppegno L; Giunta M; Cerutti I; Palomino E; Pagani F; Lastiri F; Bar D; Bezares RF; Avila G
Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):181-5. PubMed ID: 20511162
[TBL] [Abstract][Full Text] [Related]
39. The balance between cure and late effects in childhood Hodgkin's lymphoma: the experience of the German-Austrian Study-Group since 1978. German-Austrian Pediatric Hodgkin's Disease Study Group.
Schellong G
Ann Oncol; 1996; 7 Suppl 4():67-72. PubMed ID: 8836413
[TBL] [Abstract][Full Text] [Related]
40. Diffuse large cell lymphomas: identification of prognostic factors and validation of the International Non-Hodgkin's Lymphoma Prognostic Index. A Hellenic Cooperative Oncology Group Study.
Nicolaides C; Fountzilas G; Zoumbos N; Skarlos D; Kosmidis P; Pectasides D; Karabelis A; Giannakakis T; Symeonidis A; Papadopoulos A; Antoniou F; Pavlidis N
Oncology; 1998; 55(5):405-15. PubMed ID: 9732217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
